- Home
- About the University
- Find staff
- Hifaa Al Remawi
Hifaa Al Remawi
Affiliated to Research
Department of Oncology-
PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid
exposure.
Maria Lindén, Hifaa Al Remawi, Anna Fager, Levent Akyürek, Anna Rudin, Lars Ny, Sara Bjursten, Ankur Pandita, Max Levin
Immunotherapy Advances - 2026 -
Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and
nivolumab
Hifaa Al Remawi, Maria Lindén, Zhiyuan Zhao, Ankur Pandita, Anna Rudin, Lars Ny, Sara Bjursten, Max Levin
Oncoimmunology - 2025 -
Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor-induced CNS
inflammation
Sara Bjursten, Zhiyuan Zhao, Hifaa Al Remawi, Marie Studahl, Ankur Pandita, Joel Simrén, Henrik Zetterberg, Anna-Carin Lundell, Anna Rudin, Lars Ny, Max Levin
EBioMedicine - 2024